Related Experiment Video

Updated: Sep 21, 2025

Author Spotlight: Exploring the Long-Term Health Impacts of Intracytoplasmic Sperm Injection on Offspring
06:11

Author Spotlight: Exploring the Long-Term Health Impacts of Intracytoplasmic Sperm Injection on Offspring

Published on: May 17, 2024

776

Association Between Low-Dose Aspirin and Development of Gestational Diabetes: A Systematic Review and Meta-Analysis

Lauren Murphy1, Ian J Saldanha2, Kelsey Sawyer1

  • 1Department of Obstetrics and Gynecology, Alpert Medical School, Brown University, Providence, RI.

Journal of Obstetrics and Gynaecology Canada : JOGC = Journal D'Obstetrique Et Gynecologie Du Canada : JOGC
|May 31, 2022
PubMed

Insights

Low-dose aspirin for preeclampsia prevention does not increase gestational diabetes risk. However, limited study quality and quantity restrict definitive conclusions on aspirin

Area of Science:

  • Obstetrics and Gynecology
  • Pharmacology
  • Perinatal Medicine

Background:

  • Preeclampsia is a serious pregnancy complication.
  • Low-dose aspirin is used for preeclampsia prophylaxis.
  • The impact of aspirin on gestational diabetes is not fully understood.

Purpose of the Study:

  • To evaluate the association between low-dose aspirin for preeclampsia prophylaxis and the risk of gestational diabetes.
  • To assess secondary outcomes including neonatal hypoglycemia and macrosomia.

Main Methods:

  • Systematic review and meta-analysis of randomized controlled trials (RCTs) and cohort studies.
  • Searched multiple databases (Ovid MEDLINE, Embase, CINAHL, Cochrane/CENTRAL) from 1989 to 2021.
  • Assessed risk of bias using Cochrane Risk of Bias tool 2.0 and Newcastle-Ottawa Scale.

Main Results:

  • Nine studies (6 RCTs, 3 cohort studies) met inclusion criteria; only a minority were low risk of bias.
  • Low-dose aspirin was not associated with an increased risk of gestational diabetes (RR 1.18; 95% CI 0.80-1.74).
  • No studies reported data for secondary outcomes.

Conclusions:

  • Low-dose aspirin use for preeclampsia prophylaxis does not appear to increase the risk of gestational diabetes.
  • The small number and poor quality of included studies limit the interpretation of findings.
  • Further high-quality research is needed to confirm these results.
Abstract

Keywords:
aspirindiabetes, gestationalpre-eclampsia

More Related Videos

Author Spotlight: Studying the Impact of Maternal Dietary Deficiencies on Long-Term Offspring Health Outcomes03:19

Author Spotlight: Studying the Impact of Maternal Dietary Deficiencies on Long-Term Offspring Health Outcomes

Published on: June 28, 2024

511
Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes07:22

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes

Published on: March 7, 2025

388

Related Concept Videos

Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
1.3K
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
3.0K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
313
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
280
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
14.4K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
271